Globaldata's analysis focuses on three key indicators, which include HTA outcomes in the 5EU and the entry of newly priced ...

NewBiologix has given a non-exclusive technology licence to Recipharm Advanced Bio to provide pharma companies access to ...

Haya Therapeutics has secured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart ...

HLS Therapeutics has signed an agreement with Esperion Therapeutics for commercialising Nexletol and Nexlizet in Canada.

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement genAI across the agency by 30 June ...

BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform ...

Viralgen has partnered biotech company Trogenix, aiming to accelerate the development of gene therapy for glioblastoma.

The Vivo Opportunity Fund has already catalysed a plethora of medicine development via biotech investments in its first two ...

Apart from four billion-dollar deals valued at $1bn or more driven by large pharma, the industry remains cautious given the ...

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the United States.

At a time when investment has been low in biotech, establishing and maintaining good relationships with investors is vital.